98%
921
2 minutes
20
HDM2, an E3 ubiquitin ligase, is a crucial regulator of many proliferation-related pathways. It is also one of the primary regulators of p53. USP7, a deubiquitinase, also plays a key role in the regulation of both p53 and HDM2, thus forming a small regulatory network with them. This network has emerged as an important drug target. Development of a synergistic combination targeting both proteins is desirable and important for regulating this module. We have developed a small helically constrained peptide that potently inhibited p53-HDM2 interaction and exerted anti-proliferative effects on p53 cells. A combination of this peptide-when attached to cell entry and nuclear localization tags-and a USP7 inhibitor showed synergistic anti-proliferative effects against cells harboring wild-type alleles of p53. Synergistic inhibition of two important drug targets may lead to novel therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/cbdd.14255 | DOI Listing |
Arch Pharm (Weinheim)
August 2025
Department of Pharmacy and Biochemistry, Laboratory for Molecular Design & Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen, Germany.
The cysteine protease ubiquitin-specific protease 7 (USP7), also known as herpes-associated ubiquitin-specific protease (HAUSP), has gained increasing attention in recent years due to its proven overexpression in several cancer types and its role in tumorigenesis. Herein, after a design based on molecular docking experiments, we report the synthesis of a series of mildly electrophilic compounds that covalently modify the catalytic cysteine 223 in USP7 through a nucleophilic aromatic substitution (SAr) reaction. The compounds were first evaluated using differential scanning fluorimetry (DSF) to describe their influence on the melting temperature of native and mutant USP7 variants.
View Article and Find Full Text PDFJ Gynecol Oncol
July 2025
Continuing Education College, Anhui Medical University, Hefei, China.
Objective: The emergence of drug resistance brings new challenges to the clinical management of ovarian cancer (OC) patients. This study aimed to explore the role and mechanism of ubiquitin-specific peptidase 7 (USP7) on the bevacizumab resistance of OC.
Methods: The mRNA levels of USP7 and protein tyrosine kinase 2 (PTK2) were measured using quantitative real-time polymerase chain reaction.
Tissue Cell
July 2025
Department of Gynecology and Obstetrics, The Affiliated Taizhou People's Hospital of Nanjing Medical University, No. 366, the Taihu Road, Taizhou City, Jiangsu Province 225300, China.
Objective: Trophoblasts, a unique placental cell type, are sensitive to ferroptosis. Targeting trophoblast ferroptosis may be protective against trophoblast damage in patients with pre-eclampsia (PE). Herein, this study probed the role of the deubiquitinating enzyme ubiquitin-specific protease 7 (USP7) in trophoblast ferroptosis during PE.
View Article and Find Full Text PDFDrug Des Devel Ther
July 2025
Department of Anesthesiology, No. 905 Hospital of People's Liberation Army Navy, Shanghai, 200050, People's Republic of China.
Background And Objective: Myocardial ischemia-reperfusion (I/R) injury remains a significant challenge in the treatment of acute myocardial infarction, highlighting the urgent need for effective cardioprotective strategies. Sevoflurane (Sev), a widely used anesthetic, has demonstrated notable cardioprotective potential. This study investigated whether Sev mitigates ferroptosis in myocardial cells by inhibiting the USP7-mediated PTEN/PI3K/AKT pathway.
View Article and Find Full Text PDFJ Biol Chem
July 2025
Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China. Electronic address:
Receptor tyrosine kinase DDR1 (Discoidin Domain Receptor 1) interacts with the extracellular matrix (ECM) to promote tumor cell proliferation through its intracellular kinase activity, while its extracellular non-enzymatic domain creates a physical barrier for immune evasion. Although DDR1 inhibitors and antibodies have been developed, targeting DDR1 kinase activity alone cannot fully block the biological effects mediated by its scaffold function. Therefore, developing DDR1 degraders presents a potentially more effective therapeutic strategy.
View Article and Find Full Text PDF